Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Commentary|Podcasts|September 8, 2023
Pharmacy Focus - Women in Clinical Trials, Decentralized Clinical Trials
Harsha Rajasimha, PhD, MS, founder and CEO of Jeeva Informatics Solutions, discusses the importance of representation of women and minority groups in clinical trials.
Advertisement
On this episode of Pharmacy Focus, Harsha Rajasimha, PhD, MS, founder and CEO of Jeeva Informatics Solutions, discusses the importance of representation of women and minority groups in clinical trials and how decentralized clinical trials could be used to address gender disparities.
Advertisement
Related to this article
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.
Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
An investigational glypican-3–directed CAR T-cell therapy engineered to express IL-15 and IL-21 produced a complete response lasting at least 1 year in a child with chemotherapy-resistant metastatic hepatoblastoma.
Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
Target Trial Emulation Finds Limited Survival Benefit With Statins After Colorectal Cancer Treatment
Statin initiation after colorectal cancer treatment was associated with only modest survival differences after investigators accounted for biases that can exaggerate benefits in observational research.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
3
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
4
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
5